HKG:1302

3 stories mentioning HKG:1302Updated just now

Every FINWIRES story that references HKG:1302, newest first.

What's the latest news on HKG:1302?

LifeTech Scientific's Stent Graft System Included in Chinese Regulators' Special Examination Procedure

LifeTech Scientific's (HKG:1302) SureCham Aortic Arch Single-Branch Stent Graft System was admitted into the special examination and approval procedure for innovative medical devices by China's National Medical Products Administration.The device was co-developed with Shu Chang's team at Fuwai Hospital, the Chinese Academy of Medical Sciences of the National Center for Cardiovascular Diseases, a Thursday bourse filing showed.The product is indicated for the treatment of aortic dissection involving the aortic arch.

HKG:1302

Asia42d ago

LifeTech Scientific Expects Attributable Profit to Halve in H1

LifeTech Scientific (HKG:1302) expects attributable profit for the first half of 2026 to fall to about 110 million yuan to 120 million yuan, from 238.5 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.The medical device company attributed the expected decline mainly to lower revenue and a significant decrease in net exchange gains.The company expects to publish its interim results by the end of August.Shares of LifeTech were down more than 3% in Thursday morning trade.

HKG:1302

Asia65d ago

LifeTech Scientific Scraps 1.94 Billion Yuan Starway Medical Acquisition

LifeTech Scientific (HKG:1302) will not proceed with its proposed acquisition of a roughly 96.46% stake in Starway Medical Technology after failing to reach an agreement with the seller on definitive transaction documents, according to a Monday Hong Kong bourse filing.The company said the parties were unable to reach a consensus after negotiations and it no longer believes an agreement can be achieved within a reasonable timeframe.It added that continuing the process could create uncertainty and adversely affect its operations and shareholder confidence.The proposed transaction, announced in May, valued Starway at about 1.94 billion yuan and would have been funded through the issuance of convertible bonds rather than cash.Starway develops vascular interventional medical devices used to treat congenital heart defects and prevent cardioembolic stroke, an earlier filing said.

HKG:1302

Track with the FINWIRES app suite

FolioX

Track HKG:1302 in your portfolio

WheelAI

Analyze HKG:1302 options with the wheel strategy

StockInsider

See market sentiment on HKG:1302